RxDoctor Payments Data

Mark Dixon, DO

Clinical Cardiac Electrophysiology · Valparaiso, INNPI 1912980236

Payments from drug & device makers

$3,158in general payments, 2019–2025

Across 47 payments — averaging $67.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Boston Scientific$1K
  • Biosense Webster, Inc.$105
  • Novartis$73
  • Abbott$59
  • Sanofi-aventis U.S. LLC$45
  • plus $52 from 2 others

What the payments were for

  • Speaking & faculty fees$1,50048%
  • Food & beverage$1,65752%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,158 in reported general payments places this provider in the 10th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$307,666
Medicare patients
788
Services billed
2,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$198,653
XareltoRivaroxaban70$82,958
MultaqDronedarone Hcl33$57,220
Flecainide Acetate158$10,437
Amiodarone Hcl295$8,207
SotalolSotalol Hcl358$6,305
Propafenone Hcl44$2,350
Metoprolol Succinate164$2,294
Enoxaparin Sodium68$1,671
Acebutolol Hcl21$1,305
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$1,268
PaceroneAmiodarone Hcl14$1,137
Potassium Chloride53$933
Digoxin46$881
Metoprolol Tartrate64$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$45$57,22033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →